## Sources 1. [Peripheral Artery Disease: New Concepts, Treatments, and Disparities](https://www.annualreviews.org/content/journals/10.1146/annurev-med-050124-045433?TRACK=RSS) 2. [Basic Microglial Functions and How They Go Awry in Neurodegenerative Disease](https://www.annualreviews.org/content/journals/10.1146/annurev-pathmechdis-042624-114332?TRACK=RSS) 3. [Early Detection of Wellness-to-Disease Transitions in the AI Era: Implications for Pharmacology and Toxicology](https://www.annualreviews.org/content/journals/10.1146/annurev-pharmtox-062124-013423?TRACK=RSS) 4. [Decoding Connexin Hemichannels: Structure, Function, and Regulatory Mechanisms](https://www.annualreviews.org/content/journals/10.1146/annurev-physiol-050724-010008?TRACK=RSS) --- ### Basic Microglial Functions and How They Go Awry in Neurodegenerative Disease by Jordan E. McKinney, Mariko L. Bennett, and F. Chris Bennett * **Microglial Homeostasis:** Microglia are the parenchymal, tissue-resident macrophages of the spinal cord and brain, and they are critical for supporting overall brain health [1]. They function by integrating environmental cues to carry out necessary reparative processes and immune functions [1]. * **Pathogenic Shift:** In the context of neurodegenerative diseases, these normally long-lived cells lose their ability to meet the demands of their homeostatic roles [1]. Essential functions such as phagocytosis, synaptic pruning, and interferon signaling shift from being protective to becoming pathogenic [1]. * **Mechanisms of Dysfunction:** Microglial incompetence manifests in several distinct ways, including inflammatory gain of function, lysosomal overload, metabolic exhaustion, or a complete failure to respond to disease states [1]. * **Disease Case Studies:** The authors utilize inherited microgliopathies, Alzheimer's disease, and Aicardi–Goutières syndrome as primary case studies to map the trajectory of microglial function from competence to failure [1]. * **Therapeutic Potential:** The convergence of environmental and genetic factors drives this dysfunction, but understanding exactly when and how microglia go awry highlights new therapeutic pathways [1]. Emerging strategies are currently being developed to either replace or reset dysfunctional microglia, offering potential treatments for a broad spectrum of neurodegenerative conditions [1]. ### Decoding Connexin Hemichannels: Structure, Function, and Regulatory Mechanisms by Isaac E. García and Jorge E. Contreras * **Role of Hemichannels:** Connexin hemichannels act as independent conduits for the exchange of metabolites and ions, while also serving as the precursors to gap junction channels, making them pivotal for cellular communication [2]. * **Pathophysiological Implications:** These hemichannels are well-documented for their involvement in a variety of disease states, including inflammatory, neurodegenerative, and cardiovascular diseases [2]. * **Ongoing Knowledge Gaps:** Despite their known roles in disease, the exact physiological functions of connexin hemichannels in cellular signaling and tissue homeostasis remain an active area of investigation [2]. Our understanding of the mechanisms that govern their structural dynamics, permeation, gating, and overall regulation is still incomplete [2]. * **Regulatory Mechanisms:** Recent advancements have shed light on the molecular determinants that control the opening and closing of hemichannels [2]. The review emphasizes structural adaptations that modulate gating and permeation, as well as how these channels interact with broader cellular signaling networks [2]. * **Future Interventions:** By integrating structural and functional findings, the authors underscore the potential of connexin hemichannels as novel therapeutic targets for treating various diseases [2]. ### Early Detection of Wellness-to-Disease Transitions in the AI Era: Implications for Pharmacology and Toxicology by Noa Rappaport, Bartek Nogal, Kevin Perrott, Vincenzo Domina, Leroy Hood, and Nathan D. Price * **A Shift in Precision Medicine:** The field of precision medicine is moving away from static, single-analyte diagnostics and toward a dynamic, systems-level comprehension of disease and health [3]. * **The Power of AI and Multiomics:** The convergence of artificial intelligence (AI), multiomics, and systems biology is fundamentally redefining how biomarkers are discovered [3]. By utilizing multimodal and longitudinal data, researchers can map individual health trajectories to uncover early signals of disease long before traditional clinical diagnosis [3]. * **Advanced Analytical Tools:** Advancements in AI, particularly machine learning and contextualization tools like digital twins and knowledge graphs, are accelerating the clinical translation of these discoveries by enabling context-aware and predictive analyses [3]. * **Proactive Healthcare:** These technological integrations promote a paradigm shift from a reactive treatment model to a proactive, wellness-oriented approach [3]. Real-world applications of this shift include digital health monitoring and omics-informed diagnostics [3]. * **Targeted Therapeutics:** AI-driven systems biology directly informs the development of targeted pharmacology [3]. This allows for earlier interventions, highly personalized treatment plans, and the potential to successfully halt or completely reverse the progression of a disease [3]. ### Peripheral Artery Disease: New Concepts, Treatments, and Disparities by Samantha D. Minc and Katharine L. McGinigle * **Epidemiology and Risk:** Peripheral artery disease (PAD) is a prevalent, underdiagnosed atherosclerotic condition that affects more than 10 million adults in the United States [4]. It serves as a marker for systemic vascular disease and is a powerful predictor of mortality, stroke, and myocardial infarction [4]. * **Diagnostic and Treatment Landscape:** Evidence-based management strategies for PAD range from supervised exercise therapies to surgical revascularization [4]. However, the disease remains underrecognized due to variable symptom presentation, limitations in diagnostic strategies like the ankle-brachial index, and disparities in care [4]. * **Screening Debates:** There is an ongoing and evolving debate regarding PAD screening guidelines [4]. Emerging evidence suggests that targeted screening in high-risk populations is a favorable approach [4]. * **Health Disparities:** There are profound geographic, racial, and ethnic disparities in PAD-related outcomes, most notably regarding limb amputation [4]. These structural inequities persist even when adjusting for socioeconomic factors and underlying comorbidities [4]. * **Addressing the Gaps:** To effectively manage PAD and reduce amputations, comprehensive strategies are required [4]. These include policy initiatives, ensuring equitable access to care, and prioritizing early diagnosis for vulnerable populations [4].